



PATENT
PC11830ARTR

#8/C
JRL
12/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Mylari

: EXAMINER: Kevin E. Weddington

SERIAL NO.: 09/997,039

: ~~It is hereby certified~~ that this correspondence
is being deposited with the United States

FILED: November 29, 2001

: Postal Service as First Class Mail in an
envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231 on

FOR: Combination of GABA Agonists and
Aldose Reductase Inhibitors

Asst. Commissioner for Patents
Washington, DC 20231

this 18th day of December 20 02

Sir:

By 

RESPONSE UNDER 37 C.F.R. §1.111

This paper is being filed in response to the Office Action mailed May 9, 2002 in the subject patent application which has been declared abandoned by the Examiner in a subsequent Office Action mailed November 13, 2002. The Examiner stated that the reason for the abandonment was Applicants failure to respond to said May 9, 2002 Office Action. Applicants submit that said abandonment was unintentional. Applicants have enclosed herewith a petition requesting that the Commissioner revive the subject application.

-Amendments-

Please amend the application as follows:

Add the following new claims:

RECEIVED

DEC 31 2002

OFFICE OF PETITIONS

22.¹ (New) A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment
(a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and
(b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI
wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.

23.² (New) A method of claim 22 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate or a pharmaceutically acceptable salt of said GABA agonist.

24.³ (New) A method of claim 23 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin or a pharmaceutically acceptable salt of said GABA agonist.